# mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)

Source: https://onco.cc/terms/mcrpc-mhspc/  
OnCo record `mcrpc-mhspc` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Prostate cancer starts out fed by testosterone (hormone-sensitive) and shrinks when it is removed. When it learns to grow despite castrate testosterone levels it is called castration-resistant, a later and more dangerous stage with its own treatments.

## Summary

Metastatic hormone-sensitive disease (mHSPC) is treated with androgen deprivation plus an ARPI (abiraterone, enzalutamide, apalutamide, darolutamide) and sometimes docetaxel (STAMPEDE, LATITUDE, ARASENS), which delays castration resistance by years. Castration-resistant disease (CRPC), defined by PSA or radiographic progression with testosterone <50 ng/dL, arises through androgen receptor amplification, mutations, splice variants (AR-V7) and intratumoural androgen synthesis; it is treated with ARPI switch, docetaxel and cabazitaxel, PARP inhibitors for HRR mutations, 177Lu-PSMA-617 (VISION, PSMAfore) and radium-223. Non-metastatic CRPC (rising PSA, clear scans) has its own approvals. Radiographic PFS (rPFS) is the usual endpoint.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: castration-resistant; castration resistant; castrate-resistant; mCRPC; nmCRPC; CRPC; castration-sensitive; castration sensitive; hormone-sensitive; hormone sensitive; mHSPC; mCSPC; HSPC; hormone-naive; hormone-refractory; biochemical recurrence; PSA recurrence; rising PSA; PSA progression; rPFS; hormone-relapsed; hormone-relapsed metastatic prostate cancer; hormone relapsed metastatic prostate cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer

## Connected records

- terms: [Androgen deprivation therapy (ADT)](https://onco.cc/terms/adt/), [Androgen receptor pathway inhibitor (ARPI)](https://onco.cc/terms/arpi/), [Castration-resistant prostate cancer (CRPC)](https://onco.cc/terms/castration-resistance/), [Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk](https://onco.cc/terms/disease-volume-chaarted/), [Endocrine resistance](https://onco.cc/terms/endocrine-resistance/), [STAMPEDE's arms, and what each one answered](https://onco.cc/terms/prostate-stampede-arms/), [TNM staging for prostate cancer, and what changed in the 9th edition](https://onco.cc/terms/tnm-prostate-cancer/), [What follows what in castration-resistant prostate cancer](https://onco.cc/terms/prostate-crpc-sequencing/)
- cancers: [Non-metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-nmcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/), [CYP17A1 (17-alpha-hydroxylase/17,20-lyase)](https://onco.cc/targets/cyp17a1/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [Darolutamide](https://onco.cc/drugs/darolutamide/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- trials: [GETUG-AFU 15](https://onco.cc/trials/getug-afu-15/), [KEYNOTE-991](https://onco.cc/trials/keynote-991/), [LATITUDE](https://onco.cc/trials/latitude/), [PSMAfore](https://onco.cc/trials/psmafore/), [STAMPEDE](https://onco.cc/trials/stampede/), [TAX 327](https://onco.cc/trials/tax-327/), [TROPIC](https://onco.cc/trials/tropic/), [VISION](https://onco.cc/trials/vision/)
- key papers: [Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer](https://onco.cc/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/)
- biomarkers: [SPOP mutation](https://onco.cc/biomarkers/spop-mutation/)

---
JSON: https://onco.cc/api/v1/entities/mcrpc-mhspc.json